Please login to the form below

Not currently logged in

Genzyme appoints MS and rare diseases business leaders

William Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases

Genzyme has appointed leaders for its core multiple sclerosis and rare diseases businesses.

William “Bill” Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases.

“These appointments are a critical step in launching the new Genzyme,” said the company's CEO David Meeker. “Bill and Rogério are dynamic leaders with the experience, energy, vision and commitment to patients needed to move us forward.”

Sibold has more than 20 years of experience in the biopharmaceutical industry, including eight years at Biogen Idec where he worked on multiple sclerosis products Avonex and Tysabri.

He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.

Vivaldi has been with Genzyme since 1997 and was most recently president of Genzyme's renal and endocrinology business. He previously served as senior vice president and president of Genzyme Latin America.

11th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...